BCR and B-cell chronic lymphocytic leukemia: The introduction of BCR and Bcl-2 inhibitors in CLL has given rise to the concerns of the risks and benefits of allo-HSCT in high-risk CLL, which greatly decreased the application of allo-HSCTs (139, 140).